PROFASI HP INJ 10000UNIT/VIAL USP 10000 UNIT
CHORIONIC GONADOTROPIN : 10000 UNIT · DIN 00598534 · PHARMASCIENCE INC
Health Canada status: CANCELLED POST MARKET
What is PROFASI HP INJ 10000UNIT/VIAL USP?
PROFASI HP INJ 10000UNIT/VIAL USP 10000 UNIT contains CHORIONIC GONADOTROPIN : 10000 UNIT. It is listed in the Health Canada Drug Product Database under DIN 00598534, held by PHARMASCIENCE INC, supplied as POWDER FOR SOLUTION for INTRAMUSCULAR administration. Health Canada currently lists it as cancelled post market, status dated 29-Apr-2009. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 00598534 |
|---|---|
| Brand name | PROFASI HP INJ 10000UNIT/VIAL USP |
| Generic / active ingredient | CHORIONIC GONADOTROPIN : 10000 UNIT |
| Manufacturer | PHARMASCIENCE INC |
| Strength | 10000 UNIT |
| Dosage form | POWDER FOR SOLUTION |
| Route of administration | INTRAMUSCULAR |
| Schedule | Schedule D |
| ATC code | G03GA01 CHORIONIC GONADOTROPHIN |
| AHFS class | 68:18.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 29-Apr-2009 |
| Original market date | 1984-12-31 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code G03GA01 CHORIONIC GONADOTROPHIN. 2 of 6 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| CHORIONIC GONADOTROPIN FOR INJECTION, USP | 10000 UNIT | POWDER FOR SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02247459 |
| PREGNYL | 10000 UNIT | POWDER FOR SOLUTION ; KIT | ORGANON CANADA INC. | MARKETED | DIN 02182904 |
| A.P.L. - PWS-LIQ | 10000 UNIT | LIQUID ; POWDER FOR SOLUTION | WYETH-AYERST CANADA INC. | CANCELLED POST MARKET | DIN 02168936 |
| APL INJ 1000 IU/ML | 1000 UNIT | LIQUID | AYERST LABORATORIES | CANCELLED POST MARKET | DIN 00002291 |
| PROFASI HP 10000 | 10 ML | KIT ; POWDER FOR SOLUTION ; LIQUID | EMD SERONO, A DIVISION OF EMD INC., CANADA | CANCELLED POST MARKET | DIN 01925679 |
Who else supplies CHORIONIC GONADOTROPHIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. CHORIONIC GONADOTROPHIN appears in 12 registered pack listings across 4 markets, published on 4 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.